Abstract:Abstract Background Since December 2019, an outbreak of Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) initially emerged in Wuhan, China, and has spread worldwide now. Clinical features of patients with COVID-19 have been described. However, risk factors leading to in-hospital deterioration and poor prognosis in COVID-19 patients with severe disease have not been well identified. Methods In this retrospective, single-center cohort study, 1190 adult inpatients (≥ 18 years old) with laboratory-confirmed COVID-19 and determined outcomes (discharged or died) were included from Wuhan Infectious Disease Hospital from December 29, 2019 to February 28, 2020. The final follow-up date was March 2, 2020. Clinical data including characteristics, laboratory and imaging information as well as treatments were extracted from electronic medical records and compared. A multivariable logistic regression model was used to explore the potential predictors associated with in-hospital deterioration and death. Results 1190 patients with confirmed COVID-19 were included. Their median age was 57 years (interquartile range 47–67 years). Two hundred and sixty-one patients (22%) developed a severe illness after admission. Multivariable logistic regression demonstrated that higher SOFA score (OR 1.32, 95% CI 1.22–1.43, per score increase, p < 0.001 for deterioration and OR 1.30, 95% CI 1.11–1.53, per score increase, p = 0.001 for death), lymphocytopenia (OR 1.81, 95% CI 1.13–2.89 p = 0.013 for deterioration; OR 4.44, 95% CI 1.26–15.87, p = 0.021 for death) on admission were independent risk factors for in-hospital deterioration from not severe to severe disease and for death in severe patients. On admission D-dimer greater than 1 μg/L (OR 3.28, 95% CI 1.19–9.04, p = 0.021), leukocytopenia (OR 5.10, 95% CI 1.25–20.78), thrombocytopenia (OR 8.37, 95% CI 2.04–34.44) and history of diabetes (OR 11.16, 95% CI 1.87–66.57, p = 0.008) were also associated with higher risks of in-hospital death in severe COVID-19 patients. Shorter time interval from illness onset to non-invasive mechanical ventilation in the survivors with severe disease was observed compared with non-survivors (10.5 days, IQR 9.25–11.0 vs. 16.0 days, IQR 11.0–19.0 days, p = 0.030). Treatment with glucocorticoids increased the risk of progression from not severe to severe disease (OR 3.79, 95% CI 2.39–6.01, p < 0.001). Administration of antiviral drugs especially oseltamivir or ganciclovir is associated with a decreased risk of death in severe patients (OR 0.17, 95% CI 0.05–0.64, p < 0.001). Conclusions High SOFA score and lymphocytopenia on admission could predict that not severe patients would develop severe disease in-hospital. On admission elevated D-dimer, leukocytopenia, thrombocytopenia and diabetes were independent risk factors of in-hospital death in severe patients with COVID-19. Administration of oseltamivir or ganciclovir might be beneficial for reducing mortality in severe patients.

Progression, recovery and fatality in patients with SARS-CoV-2 related pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Risk factors associated with fatal outcomes of novel coronavirus infection pneumonia (COVID-19): A systematic review and meta-analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical Course and Risk Factors of Disease Deterioration in Critically Ill Patients with COVID-19.

Risk Factors for Mortality in 220 Patients with COVID-19 in Wuhan, China: A Single-Center, Retrospective Study.

Epidemiologic and Clinical Characteristics of 42 Deaths Caused by SARS-CoV-2 Infection in Wuhan, China: A Retrospective Study

Epidemiological Characteristics of Patients with Severe COVID-19 Infection in Wuhan, China: Evidence from a Retrospective Observational Study.

Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study

Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study

Identification of Risk Factors for in-Hospital Death of COVID - 19 Pneumonia

Hospitalization and Critical Care of 109 Decedents with COVID-19 Pneumonia in Wuhan, China.

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Identification of risk factors for in-hospital death of COVID - 19 pneumonia -- lessions from the early outbreak

Risk Factors Associated with Disease Severity and Clinical Outcomes for COVID-19 in Wuhan, China

Clinical Predictors of COVID-19 Disease Progression and Death: Analysis of 214 Hospitalised Patients from Wuhan, China.

Clinical Characteristics and Risk Factors for Disease Severity and Death in Patients with Coronavirus Disease 2019 in Wuhan, China

Clinical Outcomes of 402 Patients with COVID‐2019 from a Single Center in Wuhan, China

Research on pneumonia exacerbation in patients infected with SARS-CoV-2 in Wuhan, China

Clinical Features and Short-Term Outcomes of 221 Patients with COVID-19 in Wuhan, China.

Patient Predisposition at Hospital Admission Indirectly Dictates Disease Severity, Clinical Course and Outcomes of COVID-19 Pneumonia Patients in Wuhan, China